Abstract

The off-label use of modafinil, a eugeroic drug licensed to treat excessive daytime drowsiness related to narcolepsy, obstructive sleep apnea, and shift work disorder, as a cognitive enhancer has drawn a lot of attention. Modafinil's delayed onset of action and variable absorption are acknowledged drawbacks of the drug's typical oral administration(1). A potentially alternate method of delivering modafinil, intranasal delivery has drawn attention from researchers recently because of its potential for quick absorption and enhanced pharmacokinetic profile(2,3).he purpose of this review article is to give a summary of the most recent studies on modafinil intranasal administration for improving wakefulness.The purpose of this review article is to give a summary of the most recent studies on modafinil intranasal administration for improving wakefulness.

Keywords

Introduction

Due to its alleged ability to increase wakefulness and cognitive function in healthy individuals, modafinil—a eugeroic agent approved for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder—has drawn attention for its off-label use as a cognitive enhancer.(4)However, it is well recognized that the traditional oral administration of modafinil has drawbacks, including a delayed beginning of action and unpredictability in absorption, which may reduce the medication's effectiveness as a cognitive enhancer.(5)Modafinil and methylphenidate single-dose pharmacokinetics administered singly or in combination to healthy male volunteers.(3)With its potential for quicker absorption and a better pharmacokinetic profile, intranasal delivery may be able to mitigate some of the problems with oral administration.(6)Intranasal modafinil injection has been shown to be safe and effective in recent research, indicating that it may be a useful tool for improving wakefulness in both clinical and non-clinical contexts.on the use of modafinil delivered intranasally to increase wakefulness, including an outline of the mechanisms of action, benefits of intranasal delivery, a review of current studies assessing its safety and effectiveness, and possible avenues for further research.

Mechanisms of action of modafinil:

It is thought that modafinil works on the brain's several neurotransmitter systems to promote wakefulness. Modafinil is known to interact with a number of neurotransmitters, such as dopamine, norepinephrine, serotonin, and histamine, which are important neurotransmitters that regulate wakefulness, alertness, and cognitive performance, however the precise mechanisms underlying this interaction are still unclear.

1: Dopamine: One of the main mechanisms behind modafinil's benefits on alertness and cognitive enhancement is thought to be its modulation of dopamine signaling. Studies suggest that modafinil enhances dopamine release in specific brain regions, such as the nucleus accumbens and prefrontal cortex, via blocking the dopamine transporter (DAT) and boosting dopamine efflux (7)

2: Norepinephrine: Although the precise mechanism underlying this connection is unclear, modafinil has also been demonstrated to affect norepinephrine levels in the brain. Modafinil may increase arousal and attention by altering norepinephrine neurotransmission, which could contribute to its wake-promoting effects.

3: Serotonin: In some parts of the brain, modafinil may inhibit serotonin reuptake and increase serotonin release, thus modulating the serotonin system. It's possible that this interaction with the serotonin system will improve motivation, mood, and cognitive performance.

4: Histamine: The brain's histaminergic neurons play a role in sustaining arousal and encouraging wakefulness. The hypothalamus's increased production of histamine has been observed in modafinil, which may be one of the drug's impacts on enhancing wakefulness. (7).

Comparison of intranasal delivery versus oral administration of modafinil:

It is essential to compare intranasal delivery with traditional oral administration when using modafinil to increase wakefulness in order to assess the benefits and drawbacks of each method. When opposed to oral administration, intranasal distribution of modafinil offers a non-invasive approach that might result in a quicker beginning of action, higher bioavailability, and possibly even better efficacy.

1: Pharmacokinetics: Research has demonstrated that, in comparison to oral dosing, intranasal delivery of modafinil can result in higher and faster peak plasma concentrations. This suggests that intranasal administration may offer advantages in terms of pharmacokinetics, potentially leading to more consistent and predictable plasma drug levels, as well as a faster onset of action. This highlights the potential of intranasal delivery as an alternative route for administering modafinil, especially in the context of enhancing wakefulness and cognitive function. (8)

2: Bioavailability: Intranasal delivery skips the first-pass metabolism in the liver, perhaps resulting to greater bioavailability of modafinil compared to oral administration Because of its better absorption, modafinil may be given intranasally at lower doses and still have an equivalent or improved efficacy over higher oral doses. (9)

3: Onset OF Action: Because intranasal distribution of modafinil bypasses gastrointestinal breakdown and firstpass metabolism and absorbs directly through the nasal mucosa, it may have a quicker beginning of action than oral dosing. This rapid onset of action could be particularly beneficial in situations where immediate wakefulness enhancement is needed. (8) the comparison of modafinil's pharmacokinetics, absorption, and time to effect between intranasal and oral dosing, emphasizing the possible benefits of intranasal delivery for improving wakefulness.

Studies evaluating the pharmacokinetics of intranasal modafinil: Pharmacokinetic studies have assessed the body's absorption, distribution, metabolism, and excretion of modafinil when administered intranasally. In order to compare the pharmacokinetics of intranasal modafinil with oral dosing, these studies usually assess parameters including peak plasma concentration (Cmax), time to reach peak concentration (Tmax), area under the curve (AUC), and bioavailability.

Clinical trials assessing the efficacy of intranasal modafinil for enhancing wakefulness:

Clinical trials have been carried out to assess the effectiveness of intranasal modafinil in improving wakefulness in a range of populations, such as those with cognitive impairment, shift work sleep problem, and sleep disorders. These studies usually evaluate vigilance, alertness, cognitive function, and total improvement in wakefulness after modafinil is administered intranasally. Enhancement of attention, working memory, and executive function are just a few of the cognitive functions that can be improved by intranasal modafinil treatment, according to clinical investigations. (10) Faster commencement of action: According to clinical investigations, intranasal modafinil may start working more quickly than oral dosage, which could result in more noticeable improvements in alertness and cognitive function. (11) Increased wakefulness and alertness: Research has indicated that modafinil administered intranasally increases wakefulness and alertness while reducing daytime drowsiness and improving general daytime functioning. (12)

Safety profile and potential adverse effects of intranasal modafinil administration:

Safety Profile: Modafinil has a generally good safety profile, with the majority of side effects being mild to moderate in intensity. It's crucial to keep in mind that the formulation utilized for intranasal delivery may have an effect on the safety profile when thinking about intranasal administration in particular.

Potential Adverse Effects:

Nasal Irritation: Modafinil used intranasally may irritate the nasal passages, resulting in stinging, itching, or discomfort. The intranasal solution's formulation and pH may have an impact on the existence and intensity of nasal discomfort.

Headache: One of the most frequent side effects of using modafinil is headache, which can also happen when taking the drug intranasally. Everybody has a different headache onset and intensity.

Nausea: Regardless of the mode of administration, some people may have nausea or gastrointestinal distress as a possible side effect of modafinil. Insomnia: Despite the fact that modafinil is frequently used to increase wakefulness, paradoxical insomnia and irregular sleep patterns have been mentioned as possible side effects.

Cardiovascular Effects: Elevations in heart rate and blood pressure have been linked to modafinil in certain instances. When giving modafinil, even intranasally, it is crucial to keep an eye on those who have heart problems.

Mental Symptoms: Anxiety, agitation, and hallucinations are among the mental side effects that modafinil usage has occasionally been connected to. It is recommended to closely monitor for signs of psychiatric disorders. (113,14,15)

Challenges and opportunities associated with intranasal drug delivery:

Challenges: a. Anatomical and Physiological Barriers:

When it comes to intranasal drug administration, the nasal cavity offers a complex anatomical and physiological environment that can have a major impact on drug absorption. To fully appreciate the opportunities and limitations related to this route of drug administration, one must have a thorough understanding of the complexities of mucociliary clearance, enzymatic degradation, and nasal architecture.

1: Nasal Anatomy: When a medicine is delivered intranasally, the nasal cavity's unique mucosal epithelium acts as the main site of absorption. Because there are many blood arteries in this mucosal layer, medicines can more easily enter the systemic circulation. (16)

2: Mucociliary Clearance: The term "mucociliary clearance" describes how the mucus layer and cilia in the nasal passages work together to clear the nasal cavity of foreign objects and possibly entrapped medications. Drugs' residence duration may be shortened by this clearance process, which may also impact absorption. (17)       3:Enzymatic Degradation: Many enzymes, including esterases and cytochrome P450 enzymes, are found in the nasal mucosa and have the ability to metabolize and break down medications before they are taken systemically. A major obstacle to obtaining sufficient medication bioavailability through the intranasal route is enzymatic breakdown. (18)

4: Challenges: Drug absorption through the nasal mucosa is significantly hampered by the existence of enzymatic degradation and mucociliary clearance. These elements may result in inconsistent dosage and decreased drug bioavailability, which may affect the effectiveness of medications taken intranasally. (19)

5: Strategies: Scholars have investigated diverse tactics to surmount these obstacles, such as employing absorption enhancers to augment mucosal permeability, crafting mucoadhesive dosage forms mucoadhesive dosage forms to extend the duration of contact with the nasal mucosa, and devising prodrug methodologies to alleviate enzymatic degradation. It is essential to comprehend how mucociliary clearance, enzymatic degradation, and nasal anatomy affect medication absorption in order to develop efficient intranasal drug delivery methods. These intricacies also highlight the requirement for complicated formulations and medication delivery methods that can maximize drug absorption while resolving issues with the nasal environment. (20)

Dosing and Drug Formulation:

A: Dosing Challenges: a. Variable Nasal Anatomy: The variability in nasal cavity size and shape among individuals can impact the deposition and absorption of intranasal drugs, leading to dosing inconsistencies.           B: Mucociliary Clearance: The mucociliary system's quick medication clearance might shorten a drug's duration of residency in the nasal cavity, which can impact absorption and need alterations to dosage regimens.

C: Patient Factors: A number of variables, including patient technique when giving the drug, mucosal health, and congestion in the nose, might affect how effectively the medication reaches the intended spot.  

2: Drug Formulation Strategies: A. Particle Size and Formulation:

To improve nasal medication absorption, formulation design and ideal particle size are essential. Liposomal formulations and nanoparticles can enhance medication distribution and bioavailability.

B: Absorption Enhancers: Drug uptake through the nasal epithelium can be improved by using absorption enhancers, such as surfactants or permeation enhancers, which can increase mucosal permeability.

C: Mucoadhesive Dosage Forms: Mucoadhesive formulations have the potential to enhance drug absorption and bioavailability by improving nasal retention and extending drug contact with the nasal mucosa. (16 )

Formulation strategies for intranasal delivery of Modafinil 

In order to effectively absorb modafinil through the nasal mucosa, a solution or suspension that is easily sprayed into the nostrils must be developed for intranasal spray formulation. Modafinil's solubility, bioavailability, and residence time in the nasal cavity can all be improved by using nanotechnology to manufacture the drug into nanoparticles or nanosuspensions. This will increase the medication's therapeutic efficacy. By creating mucoadhesive intranasal formulations, modafinil's contact time with the nasal mucosa can be extended, improving absorption and promoting sustained release. Modafinil formulations for in situ gelling may include polymers that gel when they come into contact with the nasal mucosa, resulting in better nasal retention and prolonged drug release. Modafinil may work better when used with nasal ciliostatic drugs, permeability enhancers, or absorption promoters to boost intranasal administration. (17,18) It would be helpful to assess each of these approaches' benefits, drawbacks, and possible effects on the pharmacokinetics and pharmacodynamics of modafinil administered intravenously while talking about them.

Future Directions:

Research Opportunities:1. Nanotechnology and Novel Drug Carriers: studying the application of cutting-edge nanocarriers to improve modafinil intranasal administration, such as dendrimers, nanogels, and solid lipid nanoparticles (19)

2: Bio responsive Delivery Systems: investigating the creation of stimulus-responsive nasal drug delivery devices that have the ability to release modafinil in reaction to certain stimuli including temperature, pH, or nasal cavity enzymes (20)

3: Personalized Drug Delivery Approaches: Taking into account the possibility of individualized intranasal delivery systems based on the demands and features of each patient, including anatomical, physiological, and genetic variables (21)

4: Incorporation of Targeting Ligands: researching the addition of particular targeting ligands, including peptides or antibodies, to intranasal formulations to improve Modafinil's focused distribution to particular brain areas (22)

5: Integration of Digital Health Technologies: investigating the use of digital health technology to improve the intranasal delivery and monitoring of modafinil medication, such as smart nasal devices or sensor-based delivery systems (23)  It is crucial to weigh the possible advantages and difficulties of each strategy, as well as the consequences for patient outcomes and clinical translation, while thinking about these future paths. These approaches might offer a sneak peek at future developments and inventions that could influence modafinil intranasal delivery.

Other potential uses beyond wakefulness enhancement:

Studies and research have been done on modafinil to explore its possible use beyond improving wakefulness. These are a few possible modafinil substitute uses. Studies have indicated that modafinil may be advantageous for enhancing cognitive abilities in healthy adults, such as better decision-making, working memory, and executive function(24,25).Modafinil has been investigated as a possible substitute or supplementary treatment for ADHD, demonstrating promise in enhancing symptoms and cognitive function in those suffering from the condition(26).Research on the use of modafinil to treat fatigue brought on by illnesses like Parkinson's disease, multiple sclerosis, and cancer-related fatigue has shown promise in reducing the symptoms of exhaustion. Evidence suggests that modafinil may have antidepressant properties and may be helpful in treating depression; it may even be used in addition to prescription antidepressants (27). Due to its ability to lessen drug seeking and withdrawal symptoms, some study suggests that modafinil may be helpful in the treatment of substance use disorders, such as cocaine dependency and methamphetamine addiction. (28)

CONCLUSION:

"To sum up, the administration of modafinil by intranasal injection is a creative and promising method for increasing wakefulness. It has benefits including quick onset of action, avoiding first-pass metabolism, and possibly even raising patient compliance (30). Significant progress has been achieved in optimizing the intranasal administration of modafinil through the research of different formulation strategies, such as mucoadhesive formulations, nanoparticulate delivery systems, and nasal spray formulations (31,32).  Furthermore, there are new opportunities to improve the therapeutic efficacy and safety profile of intranasally given Modafinil due to the possibility for future breakthroughs such the integration of nanotechnology, tailored drug delivery techniques, and digital health technologies(33).In addition to improving wakefulness, modafinil's diverse pharmacological characteristics have revealed other possible uses, such as improving cognitive function, treating medical conditions-related fatigue, helping treat mood disorders, and researching substance abuse disorders.(34) These wide range of prospective applications demonstrate modafinil's adaptability and emphasize the need for more research to completely clarify the medication's therapeutic value in these areas. It is crucial to take advantage of interdisciplinary partnerships and translational research initiatives as the area of intranasal drug delivery develops further to close the gap between preclinical discoveries and clinical use. We may create a new frontier in pharmacotherapy by advancing our knowledge of nasal medication delivery systems and utilizing cutting-edge technologies. This will ultimately result in observable improvements to patient care and treatment. (37,38)  As a result, this review not only highlights the present situation with intranasal modafinil delivery but also issues a call to action for more research, development, and clinical application in this rapidly evolving sector. (39)

REFERENCES

1. Heier MS, Eriksen M, Due-Tønnessen P, Sponheim E, Lundervold AJ, Håberg AK. Cortical thickness in adult survivors of pediatric brain tumors: motor areas. J Neurooncol. 2016;127(1):123-31.
2. Volkow ND, et al. Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain. JAMA. 2009;301(11):1148-54.
3. Makris A, Stamatelopoulos K, Georgiopoulos G, Tsivgoulis G, Gialernios T, Vadikolias K. Modafinil for narcolepsy: Systematic review and metanalysis of randomized controlled trials. Sleep Med Rev. 2019;43:2736.
4. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):695-700
5. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998;38(3):276-82)
6. Thorberg FA, Walters GD, Wilkinson
7. Volkow ND, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. JAMA. 2009;301(11):1148-54).   
8. Ballon JS, et al. Prolonged effectiveness of intranasal versus oral dosing of modafinil using P300-based realtime neurocognitive monitoring. Expert Opin Drug Deliv. 2013;10(10):1283-9).
9. Thorberg FA, et al. Pharmacokinetics of modafinil after a single administration of modafinil in subjects with cirrhosis. Am J Gastroenterol. 1998;93(8):1380-7
10. Wong YN, et al. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol. 2013;28(4):332-41).
11. Smith AN, et al. A pilot study of intranasal modafinil as a treatment for fatigue in narcolepsy. J Clin Sleep Med. 2011;7(5):502-9).
12. Ballon JS, et al. Prolonged effectiveness of intranasal versus oral dosing of modafinil using P300-based real-time neurocognitive monitoring. Expert Opin Drug Deliv. 2013;10(10):1283-9).
13. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000 Mar 14;54(5):1166-75. [PubMed]
14. Brandt, M.D., Ellwardt, E., Storch, A., 2014. Short- and Long-Term Treatment with Modafinil Differentially Affects Adult Hippocampal Neurogenesis. Neuroscience 278, 267-275.
15. Sahu, S., Kauser, H., Ray, K., Kishore, K., Kumar, S., Panjwani, U., 2013. Caffeine and  modafinil promote adult neuronal cell proliferation during 48 h of total sleep  deprivation in rat dentate gyrus. Experimental Neurology 248, 470-481.
16. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 200 2;7(23):11841189.)
17. Patel VF, Liu F, Brown MB. Advances in intranasal drug delivery. J Control Release. 2019;295:187-20.
18. Djupesland PG, Skretting A. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42-62.  
19. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release. 2003;87(1-3):187-198
20. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100(1):5-28.
21. Illum L. Nasal drug delivery—possibilities, problems and solutions. Journal of controlled release. 2003 Oct 1;87(1-3):187-98
22. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release. 2000 Feb 28;65(3):403-18
23. Sharma D, Verma R, Garg S. Formulation strategies for nose to brain delivery of therapeutic agents: a comprehensive review. Journal of controlled release. 2020 Jun 10;329:894-914.
24. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Advanced drug delivery reviews. 2001 Jun 25;52(2):117-26.
25. Garg T, Malhotra S, Rath G, Goyal AK. Recent advances in nanoparticle-based drug delivery for enhanced intranasal absorption of therapeutic agents. Recent Patents on Drug Delivery & Formulation. 2021 Jun 4.
26. Tao W, Zeng X, Liu T, Wang X, Fojo AT, Meerkin D, Ma X, Farokhzad OC. Docetaxel-loaded nanoparticles based on star-shaped pH-sensitive poly (?-amino ester)–poly (ethylene glycol)–poly (?-amino ester) copolymers for cancer therapy. ACS nano. 2019 Jan 22;13(1):512-21.
27. Kopietz F, Root A, Yaakov T, Gorelick L, Arno S, Rahav G, Liberman A. Development of a personalized and easy-to-use nasal spray device for the administration of steroids: human factors and usability studies. Drug Delivery and Translational Research. 2018 Oct 1;8(5):1308-17
28. Pardridge WM. Blood-brain barrier delivery. Drug Discovery Today. 2015 Jul 1;20(7):872-8
29. Patel V, Perov S, Kong X, Klempner J, Kietz D, Aradhya T, Randolph F, Kowalczyk P, Pandita R, Allen C, Hilfinger JM. A simple, handheld nasal device enhances ad delivery to the human olfactory region. Drug Delivery. 2020 Dec 29;27(1):1084-94.
30. cancer-related fatigue, demonstrating potential efficacy in alleviating fatigue symptoms (Rammohan et al., 2002; Schwarz and Auckley, 2003).
31. Mood Disorders and Depression: There is evidence suggesting that Modafinil may have antidepressant effects and could be beneficial in the management of depression, potentially as an adjunctive treatment to standard antidepressants (DeBattista and Lembke, 2002; Calabrese et al., 2010)
32. Dackis et al., 2005; Hart et al., 2008
33. Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. European Neuropsychopharmacology. 2015 Dec 1;25(11):1865-81
34. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biological Psychiatry. 2004 Apr 15;55(10):1031-40
35. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. Journal of Neurology, Neurosurgery & Psychiatry. 2002 May 1;72(2):179-83.
36. Schwarz H, Auckley D. Electroencephalogram ?/? distribution after modafinil treatment in obstructive sleep apnea syndrome. Sleep Medicine. 2003 Sep 1;4(5):503-6.
37. DeBattista C, Lembke A. Update on modafinil for depression. Psychiatric Annals. 2002 Aug 1;32(8):427-32. 37:Calabrese J, Kimmel SE, Woyshville MJ, Rapport DJ. Predictors of response to adjunctive modafinil in a university-based outpatient program for primary mood disorders. Journal of Clinical Psychopharmacology. 2010 Aug 1;30(4):381-6.
38. Dackis CA, Kampman KM, Lynch KG, Plebani JG, Pettinati HM, Sparkman T, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Journal of Substance Abuse Treatment. 2005 Jan 1;28(3):167-75.
39. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self?administration is decreased by modafinil. Neuropsychopharmacology. 2008 Aug;33(9):2284-92.